DECANBIO

Novel MS-based strategies to Discover and Evaluate Cancer Biomarkers in urine: Application to Diagnosis of Bladder Cancer

Coordinatore	COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES    more  Organization address address: RUE LEBLANC 25 city: PARIS 15 postcode: 75015 contact info Titolo: Dr. Nome: Jérôme Cognome: Garin Email: send email Telefono: +33 4 38 78 96 56 Fax: +33 4 38 78 50 51
Nazionalità Coordinatore	France [FR]
Sito del progetto	http://decanbio.eu
Totale costo	3˙910˙866 €
EC contributo	2˙907˙412 €
Programma	FP7-HEALTH Specific Programme "Cooperation": Health
Code Call	FP7-HEALTH-2007-A
Funding Scheme	CP-FP
Anno di inizio	2008
Periodo (anno-mese-giorno)	2008-03-01   -   2012-07-31

 Partecipanti

#	participant	country	role	EC contrib. [€]
1	COMMISSARIAT A L ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES  Organization address address: RUE LEBLANC 25 city: PARIS 15 postcode: 75015 contact info Titolo: Dr. Nome: Jérôme Cognome: Garin Email: send email Telefono: +33 4 38 78 96 56 Fax: +33 4 38 78 50 51	FR (PARIS 15)	coordinator	0.00
2	"BIOMEDICAL RESEARCH FOUNDATION, ACADEMY OF ATHENS"  Organization address address: Soranou Efesiou 4 city: ATHENS postcode: 11527 contact info Titolo: Mr. Nome: Dimitris Cognome: Raptis Email: send email Telefono: +30 2 106597574 Fax: +30 2 106597571	EL (ATHENS)	participant	0.00
3	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS  Organization address address: 3 Avenue Victoria city: PARIS postcode: 75004 contact info Titolo: Mr. Nome: Michel Cognome: Bilis Email: send email Telefono: 33149812001 Fax: 33149812199	FR (PARIS)	participant	0.00
4	DIAGNOSWISS SA  Organization address address: ZI LES ILETTES SECTEUR 4 city: MONTHEY postcode: 1870 contact info Titolo: Dr. Nome: Frédéric Cognome: Reymond Email: send email Telefono: 41244714900 Fax: 41244714901	CH (MONTHEY)	participant	0.00
5	EIDGENOESSISCHE TECHNISCHE HOCHSCHULE ZURICH  Organization address address: Raemistrasse 101 city: ZUERICH postcode: 8092 contact info Titolo: Dr. Nome: Bruno Cognome: Domon Email: send email Telefono: +41 4 46 33 20 88 Fax: +41 44 633 10 51	CH (ZUERICH)	participant	0.00
6	ENTELECHON GMBH  Organization address address: INDUSTRIESTRASSE 1 city: BAD ABBACH postcode: 93077 contact info Titolo: Dr. Nome: Werner Cognome: Deininger Email: send email Telefono: +49 9419468360 Fax: +49 9419468366	DE (BAD ABBACH)	participant	0.00
7	FUNDACION CENTRO NACIONAL DE INVESTIGACIONES ONCOLOGICAS CARLOS III  Organization address address: CALLE MELCHOR FERNANDEZ ALMAGRO 3 city: MADRID postcode: 28029 contact info Titolo: Mr. Nome: Juan José Cognome: Collazo Nieto Email: send email Telefono: +34 917 328 000 Fax: +34 912 246 980	ES (MADRID)	participant	0.00
8	INSTITUT CURIE  Organization address address: 26, rue d'Ulm city: PARIS postcode: 75248 contact info Titolo: Prof. Nome: Claude Cognome: Huriet Email: send email Telefono: +33 1 44 32 40 53 Fax: +33 1 43255271	FR (PARIS)	participant	0.00
9	Luxembourg Institute of Health  Organization address address: Val Fleuri 84 city: LUXEMBOURG postcode: 1526 contact info Titolo: Mr. Nome: Daniel Cognome: Cardao Email: send email Telefono: +352 26 970 1 Fax: +352 26 970 719	LU (LUXEMBOURG)	participant	0.00

Mappa

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

 Obiettivo del progetto (Objective)

'In clinical studies, proteomics and transcriptomics allow the comparison of samples from different patients and hold special promise for the discovery of novel biomarkers and the development of “personalized medicine” approaches. Yet, translating recent discoveries into daily medical practice takes time and despite intensified researchers’ interest and investments, the rate of introduction of novel biomarkers in clinical practice is extremely disappointing. The main aim of DECanBio is to implement a strategy for protein biomarker discovery and validation relying on the use of “state of the art” mass spectrometry instrumentation for quantitative analysis of proteins. For the first time, the potential of MRM-Mass Spectrometry (MRM-MS) will be tested in the scope of a large scale validation protocol of cancer protein biomarkers. This analysis will be performed in parallel to the application of miniaturized high-throughput ELISA tests for protein quantification. DECanBio strategy will be applied to issues related to bladder cancer. Specifically, a restricted number of urinary protein biomarkers enabling the detection of recurrences during the monitoring period of patients treated for bladder tumour will be validated. The work will be performed in priority for the follow-up of low-grade superficial bladder tumours (Ta stage), which, after initial resection (without BCG therapy), are likely to evolve towards remission, recurrence, or progression to a high-grade tumor. The MRM and ELISA tests developed herein aim at the high-throughput quantification of these markers in urine. Collectively, the project has the ambition to settle a whole experimental pipe-line, from the search for new bladder cancer biomarker candidates, to their thorough evaluation and validation in clinical environment. We anticipate that the tools and knowledge that will be developed here will greatly facilitate translational studies for other diseases as well.'